日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

ATI-1777, a Topical Jak1/3 Inhibitor, May Benefit Atopic Dermatitis without Systemic Drug Exposure: Results from Preclinical Development and Phase 2a Randomized Control Study ATI-1777-AD-201.

局部用 Jak1/3 抑制剂 ATI-1777 可能在不进行全身用药的情况下使特应性皮炎受益:临床前开发和 2a 期随机对照研究 ATI-1777-AD-201 的结果

Changelian Paul, Xu Canxin, Mnich Steve, Hope Heidi, Kostecki Kourtney, Hirsch Jeff, Loh Chin-Yi, Anderson David, Blinn James, Hockerman Susan, Dick Evan, Smith Walter, Monahan Joseph, Raoof Tooraj, Forman Seth, Burt David, Barnes Brad, Gordon David, Walker Neal, Sudzina John, Tucker Stephen, Jacobsen Jon

Tapinarof Cream 1% for Extensive Plaque Psoriasis: A Maximal Use Trial on Safety, Tolerability, and Pharmacokinetics

1%他匹那罗夫乳膏治疗广泛性斑块状银屑病:安全性、耐受性和药代动力学最大剂量试验

Jett, John E; McLaughlin, Michael; Lee, Mark S; Parish, Lawrence Charles; DuBois, Janet; Raoof, Tooraj Joseph; Tabolt, Glenn; Wilson, Timothy; Somerville, Matthew C; DellaMaestra, Wayne; Piscitelli, Stephen C

A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis

鲁索替尼乳膏治疗青少年和成人特应性皮炎的最大剂量试验

Bissonnette, Robert; Call, Robert S; Raoof, Tooraj; Zhu, Zhaoyin; Yeleswaram, Swamy; Gong, Xiaohua; Lee, Mark